Granules India Limited — Q4 FY25 earnings call

Call held 28 May 2025

Management summary

Granules India reported a mixed Q4 FY25, with modest revenue growth and strong margin expansion driven by a shift towards high-margin formulation products. The company is actively addressing a US FDA warning letter at its Gagillapur facility, which is expected to cause operational slowdowns for the next two quarters. Strategic initiatives include the acquisition of Senn Chemicals for peptide therapeutics, commissioning of Phase-1 and Phase-2 of the Genome Valley formulation facility, and expansion of its oncology and ADHD portfolios, positioning the company for future growth despite near-term regulatory challenges.

Highlights

  • Q4 FY25 Revenue stood at ₹11,974 million, marking a 2% YoY growth and 5% QoQ growth.

  • Full Year FY25 Revenue was ₹44,816 million, a slight decline from ₹45,064 million in FY24.

  • Q4 FY25 Gross Margin improved to 63.4%, up 333 basis points YoY and 169 basis points QoQ, driven by higher finished dosages.

  • Q4 FY25 EBITDA was ₹2,524 million, with an EBITDA margin of 21.1%, a decrease of 67 basis points YoY but an increase of 83 basis points QoQ.

  • FY25 EBITDA grew 10% YoY to ₹9,452 million.

  • R&D spend for FY25 increased 20% to ₹2,377 million (vs ₹1,990 million in FY24).

  • Net Debt reduced to ₹7,061 million in Q4 FY25 from ₹8,289 million in Q3 FY25.

  • Gagillapur facility received an FDA warning letter on February 26, 2025, with remediation efforts expected to impact operations for another 1-2 quarters.

Concerns

  • US FDA Warning Letter for Gagillapur facility

  • Slowdown of operations due to remediation efforts

Key financials

  1. Revenue 11,974 Mn +1.8%YoY
  2. EBITDA 2,524 Mn -1.3%YoY
  3. EBITDA Margin 21.1% -0.67%YoY
  4. Gross Margin 63.4% +3.3%YoY
  5. R&D Spend 665 Mn +9.2%YoY
  6. Net Debt 7,061 Mn -14.8%QoQ

What they filed

Q1 FY27: revenue up 22.1%, net profit up 59.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue967 1,138 1,197 1,210 1,297 +34%1,388 +22%1,471 +23%1,477 +22%
EBITDA203 230 252 247 278 +37%308 +34%352 +40%339 +37%
Net profit97 118 152 113 131 +35%150 +27%202 +33%180 +59%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Operations

  • Gagillapur Production Disruption Operations · Q1 and Q2 FY26 · High confidence 1-2 quarters
    We cannot give you any guidance on this, but definitely all I can say is it's going to be better than last year. And I also want to make it clear that the slowdown on operation in Gagillapur will continue for a quarter or two.

    — Dr. Krishna Prasad C., Chairman and Managing Director

Revenue

  • FY26 Revenue Revenue · FY26 · Medium confidence better than last year
    We cannot give you any guidance on this, but definitely all I can say is it's going to be better than last year.

    — Dr. Krishna Prasad C., Chairman and Managing Director

  • Oncology Portfolio Revenue Revenue · from FY '28 onwards · Medium confidence start yielding revenues
    So overall, this is the portfolio, and we expect this portfolio to start yielding us revenues from FY '28 onwards.

    — K.V.S. Ram Rao, Joint Managing Director and Chief Executive Officer

Expenses

  • Gagillapur Remediation Expenses Expenses · Q1 and Q2 FY26 · High confidence continue
    It will continue for Q1 and Q2, but slowly declining. But definitely till Q2 we see that it should be continuing.

    — Dr. Krishna Prasad C., Chairman and Managing Director

Sales

  • Senn Chemicals Annual Sales Sales · current · High confidence CHF20 million
    So currently, they are doing roughly CHF20 million a year and with the breakeven EBITDA.

    — Mukesh Surana, Chief Financial Officer

Profitability

  • Senn Chemicals Profitability Profitability · next 1-3 quarters · Medium confidence around breakeven/slight loss
    It's sort of breakeven or slight loss as of today, yes. And we think in the next one or two quarters or three quarters it will continue to be around that level, but going forward with the new strategy, it should improve.

    — Mukesh Surana, Chief Financial Officer

Capex

  • Overall CAPEX Capex · FY26 · High confidence ₹600 crores
    So currently, we have done estimate for FY '26, FY '27 we are still working on. So FY '26, overall CAPEX estimate is about Rs. 600 crores. This includes further CAPEX, which we have to incur for Granules Life Science and also oncology and peptide investment.

    — Mukesh Surana, Chief Financial Officer

Capacity

  • GLS Phase-II Dosage Capacity Capacity · by next month onwards · High confidence 7.5 billion
    That's right. 7.5 billion is, I think, you can say 7.5 billion capacity by next month onwards, okay.

    — Dr. Krishna Prasad C., Chairman and Managing Director

Capacity Utilization

  • GLS Phase-II Capacity Utilization Capacity Utilization · by this year · Medium confidence 40-50%
    Once we get this approval, we will start full production and then I think by possibly this year, we may do about 40%, 50% capacity utilization and close to 90% by next fiscal end.

    — Dr. Krishna Prasad C., Chairman and Managing Director

  • GLS Phase-II Capacity Utilization Capacity Utilization · by next fiscal end · Medium confidence close to 90%

    — Dr. Krishna Prasad C., Chairman and Managing Director

Product Mix

  • API/PFI Contribution to Revenue Product Mix · going forward · High confidence less than 25%
    Yes, currently it is less than 25% and this is how the trend also we see going forward, as Chairman clarified in the earlier conversation. So we are producing API more for in-house consumption. So we are focusing more on formulation. So this trend of around close to 25% of API, PFI will be in that range.

    — Mukesh Surana, Chief Financial Officer

Risks & concerns

  • US FDA Warning Letter for Gagillapur facility

    high

    Received on Feb 26, 2025, following August 2024 inspection with six Form 483 observations; classified as official action initiated. Does not affect supply of approved commercial products but may temporarily impact FDA review of pending submissions.

    Management acknowledged

  • Slowdown of operations due to remediation efforts

    high

    Ongoing remediation measures have resulted in a slowdown of operations, impacting Q4 output and expected to continue for another 1-2 quarters (Q1 and Q2 FY26).

    Management acknowledged

  • API price erosion and demand issues

    medium

    Continuous price erosion and demand issues in API and PFI segments impacted sales growth. Management is shifting focus to converting API into PFIs and FDs to mitigate this.

    Management acknowledged

  • Potential US tariffs

    medium

    Management acknowledges potential impact of impending tariffs on US business, stating prices would have to increase, but believes it would be a level playing field.

    Analyst acknowledged

Areas of evasion (1)

  • Specific FY26 revenue/EBITDA guidance

Q&A highlights

2 direct
Senn Chemicals acquisition: future investment and current profitability Direct
Tushar, we are analyzing the whole situation. There is going to be a lot of CAPEX that has to come up in Switzerland. And also, we are putting up a peptide R&D facility in Hyderabad, and which will be followed by a peptide manufacturing also... It's sort of breakeven or slight loss as of today, yes. And we think in the next one or two quarters or three quarters it will continue to be around that level, but going forward with the new strategy, it should improve.

Reveals the significant future CAPEX commitment for Senn Chemicals and peptide expansion, along with its current breakeven/loss status, impacting near-term financials.

Asked by Tushar Manudhane

Gagillapur facility disruption and FY26 revenue/EBITDA guidance Partial
We cannot give you any guidance on this, but definitely all I can say is it's going to be better than last year. And I also want to make it clear that the slowdown on operation in Gagillapur will continue for a quarter or two.

Management confirms continued disruption from the FDA warning letter but avoids specific FY26 financial guidance, indicating ongoing uncertainty despite a positive directional outlook.

Asked by Tushar Manudhane

R&D spend productivity and measurement Direct
So R&D spend productivity is seen through one, the number of quality filings that we are doing both in US and Europe in ADHD and oncology segments. I think that is the first measurement that we see. The second measurement is on the value of the filings. So the NCE-1s and the first to files are the differentiated filings.

Provides insight into how Granules measures the effectiveness of its significant R&D investments, focusing on filings, differentiated products, and specific therapeutic areas like ADHD and oncology.

Asked by Tarang Agrawal

3 min read 6 chapters

Detailed narrative

Gagillapur Facility FDA Remediation Update

Granules India's Gagillapur finished dosage facility received a US FDA warning letter on February 26, 2025, following an August 2024 inspection with six Form 483 observations. While commercial product supply remains unaffected, the warning letter may temporarily impact FDA review of pending product submissions. Remediation efforts, guided by three consulting firms, have led to a slowdown in operations, which impacted Q4 output and is expected to continue for another one to two quarters. The company has tested over 1,200 batches and 2,600 swab/rinse samples, all within acceptable limits, and expects remediation expenses of approximately ₹60 crores for FY25, continuing into Q1 and Q2 FY26.

Strategic Acquisition of Senn Chemicals and Peptide Foray

Granules has strategically acquired Senn Chemicals, a Swiss-based CDMO, marking its entry into the high-growth peptide therapeutic space, including GLP-1 receptor anti-agonists. Senn Chemicals currently generates roughly CHF20 million in annual sales and operates at a breakeven or slight loss, which is expected to continue for the next 1-3 quarters. Granules plans significant CAPEX in Switzerland and for a new peptide R&D and manufacturing facility in Hyderabad, aiming to leverage Senn's capabilities for both CDMO business and Granules' own GLP-1 API and formulation development.

Genome Valley Formulation Facility Progress

The new formulation facility at Genome Valley under Granules Life Sciences is progressing well. Phase-1, with a capacity of 2.5 billion dosages, has been commissioned, and commercial dispatches of monograph products are ongoing. Phase-2, adding an additional 7.5 billion dose capacity, has been commissioned in Q4 FY25 and is expected to be fully operational by next month. The company anticipates 40-50% capacity utilization by the end of FY26 and close to 90% by the end of FY27, pending FDA and European agency inspections expected in Q2 FY26.

R&D Investment and Portfolio Expansion

Granules' R&D spend increased by 20% to ₹2,377 million in FY25, demonstrating a strong commitment to portfolio expansion. The company filed three US ANDAs and six European dossiers in Q4 FY25, bringing the total to 127 dossiers across regions. Significant progress has been made in the ADHD portfolio, with 10 products in the pipeline, including the launch of lisdexamfetamine capsules and chewable tablets in Q4 FY25. The oncology pipeline also includes around 10 products under development, with the first US ANDA and European filing submitted in Q4 FY25, expected to yield revenues from FY28 onwards.

Financial Performance and Margin Improvement

Q4 FY25 revenue grew 2% YoY to ₹11,974 million, while full-year FY25 revenue was ₹44,816 million. Gross margin significantly improved to 63.4% in Q4 FY25, up 333 basis points YoY, primarily due to a strategic shift towards higher-margin formulation products. EBITDA for Q4 FY25 was ₹2,524 million (21.1% margin), a slight YoY decline but an 83 basis point QoQ improvement. Full-year EBITDA grew 10% to ₹9,452 million, despite increased professional expenses for FDA remediation and higher R&D costs. Net debt reduced to ₹7,061 million in Q4 FY25 from ₹8,289 million in Q3 FY25.

API/PFI Strategy and Geographical Mix

Granules is strategically reducing its reliance on API sales, with the API/PFI segment contributing less than 25% of current revenue and expected to remain in that range going forward. The focus is on vertical integration, converting most APIs into PFIs and FDs for in-house consumption, especially for paracetamol where global overcapacity exists. North America remains the biggest growth driver, accounting for 79% of Q4 FY25 revenues. The company is also expanding filings in Europe (11 filings in FY25) and other ROW markets to diversify its geographical revenue mix, although the US market will continue to be a primary focus due to its size.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls